|
End-of-day quote
Taiwan S.E.
29/10/2026
|
5-day change | 1st Jan Change | ||
| 56.90 TWD | +0.18% |
|
+0.18% | +6.26% |
| Market Cap | 10.17B 313M 281M 260M 235M 440M 29.84B 445M 3.11B 1.24B 15.62B 1.18B 1.15B 49.58B | P/E 2024 |
12.6x | P/E 2025 | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 8.73B 269M 241M 223M 202M 378M 25.63B 382M 2.67B 1.06B 13.41B 1.01B 988M 42.57B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.29x |
| Free-Float |
44.21% | Yield 2024 |
4.52% | Yield 2025 | 3.4% |
| 1 day | +0.18% | ||
| 1 week | +0.18% | ||
| Current month | +1.07% | ||
| 1 month | +1.25% | ||
| 3 months | -0.70% | ||
| 6 months | +2.44% | ||
| Current year | +6.26% |
| 1 week | 56.6 |  | 57.4 |
| 1 month | 55.6 | | 58.3 |
| Current year | 53.55 | | 60.55 |
| 1 year | 50.18 | | 60.55 |
| 3 years | 46.55 | | 72.18 |
| 5 years | 34.86 | | 72.36 |
| 10 years | 24.86 | | 72.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tzu-Ting Fan
CEO | Chief Executive Officer | - | 30/05/2006 |
Shu Hua Chen
IRC | Investor Relations Contact | - | - |
Wei Jen Chen
PRN | Corporate Officer/Principal | - | 01/04/2001 |
| Director | Title | Age | Since |
|---|---|---|---|
Chin Tsai Fan
CHM | Chairman | - | 30/06/1967 |
Tzu-Ting Fan
CHM | Chairman | - | - |
Yuan Te Li
BRD | Director/Board Member | - | 06/06/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.18% | +0.18% | +12.57% | +2.78% | 313M | |
| +6.69% | +4.71% | +68.19% | +141.87% | 1,148B | |
| +1.38% | +2.68% | +47.26% | +86.89% | 652B | |
| +1.20% | +1.49% | +28.56% | +103.98% | 505B | |
| +0.80% | +2.47% | +54.30% | +66.51% | 384B | |
| +4.91% | +0.10% | +70.24% | +43.54% | 348B | |
| +2.56% | +2.73% | +34.42% | +56.45% | 294B | |
| +2.37% | +0.40% | +3.76% | +27.54% | 264B | |
| +1.68% | +2.50% | +57.12% | +74.19% | 244B | |
| +1.47% | +2.68% | +36.20% | +107.54% | 197B | |
| Average | +2.32% | +1.27% | +41.26% | +71.13% | 403.75B | |
| Weighted average by Cap. | +3.27% | +1.50% | +49.80% | +93.14% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 6.79B 209M 188M 174M 157M 294M 19.93B 297M 2.08B 826M 10.43B 785M 769M 33.1B | 7.02B 216M 194M 180M 163M 304M 20.61B 307M 2.15B 855M 10.79B 812M 795M 34.24B |
| Net income | 881M 27.13M 24.34M 22.51M 20.38M 38.08M 2.58B 38.54M 269M 107M 1.35B 102M 99.67M 4.29B | 928M 28.59M 25.65M 23.71M 21.48M 40.12M 2.72B 40.61M 284M 113M 1.42B 107M 105M 4.52B |
| Net Debt | -1.24B -38.32M -34.38M -31.79M -28.79M -53.79M -3.65B -54.44M -380M -151M -1.91B -144M -141M -6.06B | -1.44B -44.26M -39.71M -36.71M -33.25M -62.12M -4.22B -62.87M -439M -175M -2.21B -166M -163M -7B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | TWD 56.90 | +0.18% | 97,078 |
| 28/10/26 | TWD 56.80 | -0.53% | 132,612 |
| 27/10/26 | TWD 57.10 | +0.18% | 306,425 |
| 22/10/26 | TWD 57.00 | +0.35% | 139,903 |
| 21/10/26 | TWD 56.80 | -0.18% | 228,324 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1720 Stock
Select your edition
All financial news and data tailored to specific country editions
